Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication March 9, 2004
- Accepted for publication April 27, 2004
- Published online July 29, 2004.
Copyright & Usage
© 2004 American Society of Nephrology
Author Information
- Geoffrey A. Block*,
- Preston S. Klassen†,
- J. Michael Lazarus‡,
- Norma Ofsthun‡,
- Edmund G. Lowrie‡ and
- Glenn M. Chertow§
- *Denver Nephrology Associates, Denver, Colorado; †Amgen Inc., Thousand Oaks, California; ‡Fresenius Medical Care North America, Lexington, Massachusetts; and §Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California
- Correspondence to Dr. Glenn M. Chertow, Department of Medicine Research, University of California San Francisco, UCSF Laurel Heights Suite 430, 3333 California Street, San Francisco, CA 94118-1211. Phone: 415-476-2173; Fax: 415-476-9531; E-mail: chertowg{at}medicine.ucsf.edu
Statistics from Altmetric.com
Article usage
Cited By...
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Jump to section
More in this TOC Section
Cited By...
- Microvasculopathy, Luminal Calcification and Premature Aging in Fetuin-A Deficient Mice
- Serum Phosphate and Microvascular Function in a Population-Based Cohort
- Lack of Awareness of Dietary Sources of Phosphorus Is a Clinical Concern
- Parathyroidectomy in the Management of Secondary Hyperparathyroidism
- Anion Gap as a Determinant of Ionized Fraction of Divalent Cations in Hemodialysis Patients
- A Pilot Study of OkKidney, a Phosphate Counting Application in Patients on Peritoneal Dialysis
- Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders
- Impact of nutritional index on the association between phosphorus concentrations and mortality in haemodialysis patients: a cohort study from dialysis outcomes and practice pattern study in Japan
- Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function
- Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial
- Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis
- Fibroblast growth factor 23 as novel biomarker for early risk stratification after ST-elevation myocardial infarction
- Association of Serum Phosphorus Concentration with Mortality and Graft Failure among Kidney Transplant Recipients
- Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study
- Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial
- Inorganic Phosphate Activates the AKT/mTORC1 Pathway and Shortens the Life Span of an {alpha}-Klotho-Deficient Model
- Association Between Serum Phosphate Levels and Stroke Risk in Patients Undergoing Hemodialysis: The Q-Cohort Study
- Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States
- Intracellular Phosphate Dynamics in Muscle Measured by Magnetic Resonance Spectroscopy during Hemodialysis
- Phosphate Toxicity in CKD: The Killer among Us
- Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis
- Serum PTH reference values established by an automated third-generation assay in vitamin D-replete subjects with normal renal function: consequences of diagnosing primary hyperparathyroidism and the classification of dialysis patients
- Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism
- Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study
- Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014
- Uncorrected and Albumin-Corrected Calcium, Phosphorus, and Mortality in Patients Undergoing Maintenance Dialysis
- Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial
- Has Dialysis Payment Reform Led to Initial Racial Disparities in Anemia and Mineral Metabolism Management?
- Recent Changes in Therapeutic Approaches and Association with Outcomes among Patients with Secondary Hyperparathyroidism on Chronic Hemodialysis: The DOPPS Study
- Telomeric G-Tail Length and Hospitalization for Cardiovascular Events in Hemodialysis Patients
- Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial
- Comparative Mortality-Predictability Using Alkaline Phosphatase and Parathyroid Hormone in Patients on Peritoneal Dialysis and Hemodialysis
- A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stages 3-4 CKD
- Plasma-Parathyroid Hormone Is Associated With Subclinical and Clinical Atherosclerotic Disease in 2 Community-Based Cohorts
- Calcium Balance and Negative Impact of Calcium Load in Peritoneal Dialysis Patients
- Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes: Pooled Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trials
- What Can We Learn from the Saga of Chitosan Gums in Hyperphosphatemia Therapy?
- Association of serum alkaline phosphatase with mortality in non-selected European patients with CKD5D: an observational, three-centre survival analysis
- Phosphorus and the Kidney: What Is Known and What Is Needed
- Increasing Dietary Phosphorus Intake from Food Additives: Potential for Negative Impact on Bone Health
- CKD-Mineral and Bone Disorder and Risk of Death and Cardiovascular Hospitalization in Patients on Hemodialysis
- Evidence-Based Cardiology in Hemodialysis Patients
- The Connection between Dietary Phosphorus, Cardiovascular Disease, and Mortality: Where We Stand and What We Need to Know
- Single FGF-23 Measurement and Time-Averaged Plasma Phosphate Levels in Hemodialysis Patients
- Parathyroidectomy and Heart Rate Variability in Patients with Stage 5 CKD
- Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
- 24-Hour Urine Phosphorus Excretion and Mortality and Cardiovascular Events
- Serum FGF23 and Risk of Cardiovascular Events in Relation to Mineral Metabolism and Cardiovascular Pathology
- Mechanistic Insights into Vascular Calcification in CKD
- Association of Pre-Kidney Transplant Markers of Mineral and Bone Disorder with Post-Transplant Outcomes
- Prescription Patterns and Mineral Metabolism Abnormalities in the Cinacalcet Era: Results from the MBD-5D Study
- Normal and Pathologic Concentrations of Uremic Toxins
- Racial Differences in Markers of Mineral Metabolism in Advanced Chronic Kidney Disease
- Acute Effects of Very-Low-Protein Diet on FGF23 Levels: A Randomized Study
- Effects of Frequent Hemodialysis on Measures of CKD Mineral and Bone Disorder
- Efficacy and Safety of Paricalcitol Therapy for Chronic Kidney Disease: A Meta-Analysis
- Renal Phosphate Loss in Long-Term Kidney Transplantation
- Vitamin D Therapy in Chronic Kidney Disease and End Stage Renal Disease
- Interaction of Time-Varying Albumin and Phosphorus on Mortality in Incident Dialysis Patients
- Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women
- Association of Pretransplant Serum Phosphorus with Posttransplant Outcomes
- Phosphate REINs in the Renoprotective Benefit of ACE Inhibition
- FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis